COVID-19Regulatory

Experimental coronavirus treatment using antiviral remdesivir expanded by developer Gilead

March 30, 2020 / By James Rogers | Fox News

Biotech company Gilead Sciences is expanding access to its antiviral drug remdesivir as an experimental coronavirus treatment.

In an open letter sent out Saturday, Gilead CEO Daniel O’Day said the company is carefully ramping up its efforts to make remdesivir available to coronavirus patients. The antiviral has previously been used to treat Ebola patients.

Remdesivir, which is awaiting regulatory approval as a coronavirus treatment, is being used in a number of clinical trials across the globe. In a project designed by regulators, it has also been made available, on an individual basis, to some severely ill patients who cannot participate in clinical trials.

“When the news of the coronavirus first emerged, Gilead immediately began to investigate the potential of remdesivir, a medicine we had been studying for many years as part of our extensive research in antivirals,” O’Day explained. “Remdesivir had never been approved for use but based on what we had learned to date, we knew it might have potential with the novel coronavirus. Since then, we have been working with the greatest sense of urgency and responsibility to determine whether Remdesivir does indeed work against COVID-19.”

READ THE REST HERE

Print Friendly, PDF & Email
Tags

Mike Adams

Mike Adams is a medical device sales leader with extensive clinical experience in spine and biologics and a nationwide distribution network built over the last 10+ years in the industry. He has held various leadership positions in healthcare and device including Distributor Partner, Hospital COO and Spine VP of Sales. He currently leads the commercialization strategy for OrthoSpine Partners and is a Distributor Principal at Novel Medical. Because of his unique career path, Mike has the ability to see the healthcare business from multiple perspectives making him passionate about building strategic partnerships that help reduce overall costs, drive innovation, and cultivate growth for new markets.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
Close